Author: BGI Genomics
Published: 2024/11/06
Publication Type: Research, Study, Analysis – Peer-Reviewed: Yes
Topic: Colorectal Cancers (Publications Database)
Page Content: Synopsis Introduction Main Item
Synopsis: Diagnostic accuracy of multi-target stool DNA check for colorectal most cancers screening and detecting in Thailand.
Why it issues: The analysis described within the article is critical as a result of it demonstrates the effectiveness of stool DNA testing as a non-invasive different for colorectal most cancers screening in Thailand. This discovering is especially priceless in a rustic the place colonoscopy assets are restricted and cultural limitations might discourage conventional screening strategies. The research exhibits that stool DNA testing can detect each colorectal most cancers and superior precancerous lesions with excessive sensitivity, probably bettering early detection charges and decreasing mortality from this prevalent most cancers. By providing a extra accessible and culturally acceptable screening possibility, this analysis may lead to elevated participation in colorectal most cancers screening applications, finally saving lives and decreasing healthcare prices in Thailand and probably different nations with comparable challenges – Disabled World.
Introduction
A latest potential cross-sectional research in Thailand demonstrates that multi-target stool DNA testing is extremely delicate and particular for detecting colorectal most cancers (CRC) amongst Thai people. Researchers imagine that this testing technique may function a viable non-invasive different to colonoscopy, particularly in settings the place colonoscopy is much less accessible or much less accepted by sufferers.
Main Item
This research was carried out by BGI Genomics in 2023, in collaboration with Professor Varut Lohsiriwat’s workforce from the Faculty of Medicine, Siriraj Hospital, Mahidol University, Thailand. The analysis workforce included Professor Varut Lohsiriwat, Dr. Aitsariya Mongkhonsupphawan (M.D, Ph.D, Faculty of Medicine, Siriraj Hospital, Mahidol University), and Pornraksa Ovartchaiyapong (Lecturer, Faculty of Medicine, Siriraj Hospital, Mahidol University). The research was printed within the Asian Pacific Journal of Cancer Prevention (APJCP) in October 2024.
BGI Genomics, headquartered in Shenzhen, China, is the world’s main built-in options supplier of precision drugs. Our companies cowl greater than 100 nations and areas, involving greater than 2,300 medical establishments.
Researchers targeted on evaluating the diagnostic efficiency of the multi-target stool DNA testing for detecting CRC and superior adenoma, utilizing colonoscopy because the reference normal. The research included each asymptomatic and symptomatic sufferers who underwent stool DNA testing adopted by colonoscopy. The multi-target stool DNA check focused methylation statuses of SDC2, ADHFE1, and PPP2R5C genes. Sensitivity, specificity, and different diagnostic parameters have been analyzed.
In the research, information from 274 sufferers (imply age 62 years, with a predominantly feminine cohort at 60.6%) have been evaluated. Colorectal most cancers was recognized in 17.2% of members, whereas 6.2% have been discovered to have superior adenomas, that are precursors to most cancers. The multi-target stool DNA check, a non-invasive screening technique, yielded spectacular outcomes: it detected CRC with a sensitivity of 91.5% and a specificity of 90.3%, precisely figuring out most cancers in over 90% of instances. The check’s sensitivity was constant throughout each right-sided and left-sided colon lesions, at 92.3% and 91.2%, respectively.
For superior colorectal neoplasms, which embrace each CRC and superior adenomas, the check demonstrated a sensitivity of 75% and a specificity of 91.9%, marking it as a promising device for the early detection of great colorectal situations. These findings spotlight the check’s potential as an efficient screening possibility for detecting CRC, particularly for bigger lesions, though some limitations stay for detecting smaller-sized abnormalities.
BGI Genomics’ COLOTECT® stool DNA testing kits have been used for pattern and uncooked information assortment. COLOTECT® is a non-invasive device for early colorectal most cancers detection based mostly on DNA methylation testing, concentrating on the methylation profile of colorectal exfoliated cells to assess the chance of colorectal most cancers and superior adenomas. This device requires no particular gear, imposes no dietary restrictions, and is solely non-invasive. In latest years, DNA methylation-based colorectal most cancers detection has gained recognition, being integrated into a number of CRC screening pointers and professional consensus worldwide.
The research outcomes point out that multi-target stool DNA testing is extremely delicate and particular for CRC detection amongst Thai people. This testing may present a viable non-invasive different to colonoscopy, particularly in settings the place colonoscopy is much less accessible or much less accepted by sufferers.
In June 2024, to advance the worldwide understanding of CRC and discover methods to shut the attention hole, BGI Genomics invited Prof. Varut Lohsiriwat from Mahidol University and Dr. Zhu Shida from BGI Genomics to share insights after reviewing the BGI Genomics 2024 Global State of Colorectal Cancer Awareness Report.
As early as 2022, BGI Genomics Southeast Asia workforce established an in depth partnership with Professor Varut Lohsiriwat from the Faculty of Medicine, Siriraj Hospital, Mahidol University, inviting him to take part within the BGI Genomics abroad science training program “Your Health, Our Concern.” In this program, Professor Lohsiriwat shared priceless data and insights on colorectal most cancers therapy.
With help from international consultants, corresponding to Professor Varut’s workforce, and superior genetic sequencing know-how like BGI Genomics’ COLOTECT® Stool DNA Methylation Test, which extracts DNA from intestinal exfoliated cells in stool samples and detects aberrant methylation in genes associated to CRC (SDC2, ADHFE1, and PPP2R5C) by means of fluorescent PCR, we count on to considerably scale back the worldwide burden of CRC.
Don’t Forego Colonoscopy for New Blood-Based Colon Cancer Tests: Colonoscopies and stool assessments are simpler at detecting early cancers and precancerous polyps than the brand new rising blood assessments.
Attribution/Source(s):
This peer reviewed publication was chosen for publishing by the editors of Disabled World due to its vital relevance to the incapacity neighborhood. Originally authored by BGI Genomics, and printed on 2024/11/06, the content material might have been edited for fashion, readability, or brevity. For additional particulars or clarifications, BGI Genomics might be contacted at bgi.com/us/dwelling. NOTE: Disabled World doesn’t present any warranties or endorsements associated to this text.
Page Information, Citing and Disclaimer
Disabled World is a complete on-line useful resource that gives data and information associated to disabilities, assistive applied sciences, and accessibility points. Founded in 2004 our web site covers a variety of matters, together with incapacity rights, healthcare, training, employment, and impartial residing, with the purpose of supporting the incapacity neighborhood and their households.
Cite This Page (APA): BGI Genomics. (2024, November 6). COLOTECT DNA Stool Test Viable Alternative to Colonoscopy. Disabled World. Retrieved November 7, 2024 from www.disabled-world.com/well being/most cancers/colorectal/colotect.php
Permalink: <a href=”https://www.disabled-world.com/well being/most cancers/colorectal/colotect.php”>COLOTECT DNA Stool Test Viable Alternative to Colonoscopy</a>: Diagnostic accuracy of multi-target stool DNA check for colorectal most cancers screening and detecting in Thailand.
Disabled World offers normal data solely. Materials introduced are by no means meant to substitute for certified medical care. Any third celebration providing or promoting doesn’t represent an endorsement.